Managing chemotherapy side effects with a smartphone symptom app plus telenursing
Official title: Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients
Run by Ulsan University Hospital · NCT07405931 · Data updated 2026-11-12
This trial tests whether a smartphone symptom-reporting app combined with a standardized telenursing program helps adults starting first-cycle chemotherapy for gastric, lung, breast, or colon cancer manage treatment side effects.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 19 Years and up |
| Sex | All |
| Enrollment | 414 (estimated) |
| Sponsor | Ulsan University Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 5 sites (Busan and 4 other locations) |
| Status | Recruiting |
| Started | July 9, 2025 |
| Main results expected | March 2026 |
| Study ends | September 2026 |
| Registry record updated | February 12, 2026 |
| Trial ID | NCT07405931 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (≥19 years) with early or advanced gastric, lung, breast, or colon cancer who are starting first-cycle chemotherapy with a new anticancer drug, can use a smartphone easily, and can read and understand Korean.
✕Probably not a fit
Patients with significant communication barriers (cognitive, visual, or hearing impairment), those who cannot read Korean, those unable to use a smartphone, or those not starting a first-cycle chemotherapy are unlikely to benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter randomized controlled trial in South Korea comparing a digital health platform (Smart Cancer Care Plus) plus standardized telenursing to usual care for adults beginning first-cycle chemotherapy with a new anticancer agent. Participants use a smartphone app to report symptoms (ePRO), receive guidance for self-management, and get follow-up and coaching from trained telenurses according to a standardized protocol. The trial measures clinical outcomes and healthcare costs to determine both effectiveness and cost-effectiveness of the combined digital-plus-telecare approach. Enrollment requires the ability to read and use a smartphone and provision of informed consent at one of the participating hospitals.
Why it matters
Potential benefit: If successful, this approach could reduce uncontrolled chemotherapy side effects, lower emergency visits or hospital stays, and improve patients' comfort and quality of life while potentially saving healthcare costs.
How similar studies have gone: Previous oncology studies using electronic patient-reported outcomes and telehealth have shown improved symptom control and fewer acute care visits, though combining a standardized telenursing protocol with an integrated ePRO platform is less extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 19 years or older * Diagnosed with early or advanced gastric, lung, breast, or colon cancer * Starting first-cycle chemotherapy with a new anticancer agent * Able to use a smartphone without difficulty * Willing to provide informed consent to participate in the study Exclusion Criteria: * Individuals who have difficulty communicating due to cognitive impairment, visual impairment, hearing impairment, or other reasons * Individuals who cannot read, write, or understand Korean * Other individuals deemed inappropriate for participation by the investigators
Where it's running
-
Kosin University Gospel Hospital
Busan, South Korea Recruiting -
National Cancer Center, Korea
Goyang, South Korea Recruiting -
Gyeongsang National University
Jinju, South Korea Recruiting -
Ulsan University Hospital
Ulsan, South Korea Recruiting -
Gachon University Gil Medical Center
Incheon, South Korea Not yet recruiting
Study contacts
- Principal investigator: Sujin Koh, Doctor of Philoshophy — Ulsan University Hospital
- Study coordinator: Minseon Song, bachelor's degree
- Email: 9204564@uuh.ulsan.kr
- Phone: +82522507018
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ovarian suppression after ZOLADEX 10.8 mg in premenopausal women with HR+ breast cancer
This study tests how well ZOLADEX 10.8 mg can suppress ovaries in premenopausal women with HR+ breast cancer.
-
Finding better ways to detect resistance to antibody‑drug conjugates in solid tumors and identify useful biomarkers
This trial tests whether tissue and blood biomarkers collected before and after treatment can reveal why antibody‑drug conjugates stop working in adults with advanced breast, gastric, urothelial, or non‑small cell lung cancer.
-
HS-10502 combination treatment for advanced solid tumors
This study will test whether the oral drug HS-10502, given with other cancer medicines, is safe and can help people with advanced solid tumors such as recurrent ovarian cancer, HER2‑negative or triple‑negative breast cancer, and advanced prostate cancer.
-
Evaluating BBO-10203 for advanced solid tumors
This study is testing a new treatment called BBO-10203, alone and with another drug, to see if it can help people with advanced solid tumors, including certain types of breast cancer.
-
Psychosocial intervention for managing symptoms in advanced cancer patients
This study is testing a new telehealth program called ENGAGE to see if it can help people with advanced cancer manage their symptoms and improve their quality of life.
-
SPADE procedure for upper stomach cancer
A multicenter study will test the SPADE operation, a special stomach reconnection technique, in patients with early upper-stomach cancer undergoing proximal gastrectomy to see if it is safe and feasible.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.